“Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle

ENGAGE and EMERGE: Truth and consequences?

(2021) Lewis H. Kuller et al.   Alzheimers & Dementia

Alzheimer's disease

(2021) Philip Scheltens et al.   LANCET

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

(2021) Jeffrey Cummings et al.   Alzheimers Research & Therapy

A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer’s Disease

(2021) Sanchari Mukhopadhyay et al.   JOURNAL OF ALZHEIMERS DISEASE

The FDA Approves Aducanumab for Alzheimer’s Disease, Raising Important Scientific Questions1

(2021) Jack C. de la Torre et al.   JOURNAL OF ALZHEIMERS DISEASE

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

(2021) Stephen Salloway et al.   NATURE MEDICINE

Aducanumab for Alzheimer’s disease: A regulatory perspective

(2021) Robert Nisticò et al.   PHARMACOLOGICAL RESEARCH

The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval

(2021) Kerrington Powell et al.   JAMA Oncology

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease

(2021) William L. Herring et al.   Neurology and Therapy

Aducanumab and disease modifying treatments for Alzheimer's disease

(2021) Emily Thomas et al.   Progress in Neurology and Psychiatry

How the US Food and Drug Administration’s approval of aducanumab for Alzheimer's disease has implication for oncology and beyond

(2021) Mark P. Lythgoe et al.   EUROPEAN JOURNAL OF CANCER

Aducanumab and the “post-amyloid” era of Alzheimer research?

(2021) Erik S. Musiek et al.   NEURON

Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration’s Actions

(2020) Alyson Haslam et al.   MAYO CLINIC PROCEEDINGS

Anti-Amyloid-β Protein agents for the treatment of Alzheimer’s Disease: An update on emerging drugs

(2020) Madia Lozupone et al.   EXPERT OPINION ON EMERGING DRUGS

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease

(2020) Steven S. Plotkin et al.   NEUROBIOLOGY OF DISEASE

Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer’s Disease

(2020) Joakim Bastrup et al.   JOURNAL OF ALZHEIMERS DISEASE

Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018

(2020) Patrick C. DeMartino et al.   JAMA Internal Medicine

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

(2019) Francesco Panza et al.   Nature Reviews Neurology

Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics

(2019) Sneham Tiwari et al.   International Journal of Nanomedicine

Amyloid-beta modulates low-threshold activated voltage-gated L-type calcium channels of arcuate neuropeptide Y neurons leading to calcium dysregulation and hypothalamic dysfunction

(2019) Makoto Ishii et al.   JOURNAL OF NEUROSCIENCE

A resurrection of aducanumab for Alzheimer's disease

(2019) Lon Schneider   LANCET NEUROLOGY

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

(2018) Christopher H. van Dyck   BIOLOGICAL PSYCHIATRY

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

(2018) Joseph W. Arndt et al.   Scientific Reports

Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) Emma Nichols et al.   LANCET NEUROLOGY

Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease

(2017) Kanchana K. Gamage et al.   JOURNAL OF NEUROSCIENCE

Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy

(2016) Jing Liu et al.   DRUGS & AGING

Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice

(2016) Ksenia V. Kastanenka et al.   JOURNAL OF NEUROSCIENCE

Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs

(2016) Chul Kim et al.   MAYO CLINIC PROCEEDINGS

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Immunotherapeutic Approaches for Alzheimer’s Disease

(2015) Thomas Wisniewski et al.   NEURON

Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease

(2015) Sagar H. Barage et al.   NEUROPEPTIDES

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Calcium regulation of neural rhythms, memory and Alzheimer's disease

(2013) Michael J. Berridge   JOURNAL OF PHYSIOLOGY-LONDON

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease

(2013) Chris G. Parsons et al.   NEUROTOXICITY RESEARCH

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease

(2010) Francesco Panza et al.   Immunotherapy

Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease

(2009) John C. Morris et al.   ARCHIVES OF NEUROLOGY

Aβ Plaques Lead to Aberrant Regulation of Calcium Homeostasis In Vivo Resulting in Structural and Functional Disruption of Neuronal Networks

(2008) Kishore V. Kuchibhotla et al.   NEURON